000126395 001__ 126395 000126395 005__ 20240319081011.0 000126395 0247_ $$2doi$$a10.1111/jam.15699 000126395 0248_ $$2sideral$$a130128 000126395 037__ $$aART-2022-130128 000126395 041__ $$aeng 000126395 100__ $$aSerrano, Laura 000126395 245__ $$aAssessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection 000126395 260__ $$c2022 000126395 5060_ $$aAccess copy available to the general public$$fUnrestricted 000126395 5203_ $$aAims: Presence of anti-S1 region of SARS-CoV-2 spike protein was analysed, at two and eight months, in 477 immunocompetent healthcare workers in Zaragoza, Spain, vaccinated with mRNA-1273 (Moderna) or BNT162b2 (Pfizer). Methods and results: Antibody analysis was performed with Alinity i System (Abbott). At 2 months, 100% of vaccinated had anti-S1 IgG (mean = 13, 285 AU ml-1). This value was significantly higher with Moderna (18, 192 AU ml-1) than with Pfizer (10, 441 AU ml-1). The mean value of anti-S1 IgG after vaccination was significantly higher in patients with than without previous infection (18, 539 vs. 7919 AU ml-1); in both groups was significantly higher with Moderna than with Pfizer (21, 881 vs. 15, 733 AU ml-1 and 11, 949 vs. 6387 AU ml-1), respectively. At 8 months, 100% of patients were IgG positive, with higher levels with Moderna than with Pfizer. Nevertheless, in ensemble of cases, a mean decrease of antibody levels of 11, 025 AU ml-1 was observed. Conclusion: At 2 and 8 months after vaccination, IgG response persists with both vaccines but with important decrease which suggests the need for revaccination. Significance and impact of study: The study contributes to know the immune status after vaccination with two of more used anti-SARS-CoV-2 vaccines. This knowledge is important for establishing the best vaccination strategy. © 2022 The Authors. Journal of Applied Microbiology published by John Wiley & Sons Ltd on behalf of Society for Applied Microbiology. 000126395 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000126395 590__ $$a4.0$$b2022 000126395 592__ $$a0.774$$b2022 000126395 591__ $$aMICROBIOLOGY$$b58 / 135 = 0.43$$c2022$$dQ2$$eT2 000126395 593__ $$aApplied Microbiology and Biotechnology$$c2022$$dQ2 000126395 591__ $$aBIOTECHNOLOGY & APPLIED MICROBIOLOGY$$b55 / 158 = 0.348$$c2022$$dQ2$$eT2 000126395 593__ $$aMedicine (miscellaneous)$$c2022$$dQ2 000126395 593__ $$aBiotechnology$$c2022$$dQ2 000126395 594__ $$a6.7$$b2022 000126395 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000126395 700__ $$0(orcid)0000-0002-0036-6630$$aAlgarate, Sonia$$uUniversidad de Zaragoza 000126395 700__ $$aHerrero-Cortina, Beatriz 000126395 700__ $$aBueno, Jessica 000126395 700__ $$aGonzález-Barriga, Maria T. 000126395 700__ $$aDucons, Maria 000126395 700__ $$aMontero-Marco, Jesica 000126395 700__ $$aAcha, Beatriz 000126395 700__ $$aTaboada, Ana 000126395 700__ $$aSanz-Burillo, Pilar 000126395 700__ $$aYuste, Cristina 000126395 700__ $$0(orcid)0000-0001-5134-1006$$aBenito, Rafael$$uUniversidad de Zaragoza 000126395 700__ $$aRIPOVAC, Study Group 000126395 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología 000126395 773__ $$g133, 3 (2022), 1969-1974$$pJ. appl. microbiol.$$tJournal of Applied Microbiology$$x1364-5072 000126395 8564_ $$s341219$$uhttps://zaguan.unizar.es/record/126395/files/texto_completo.pdf$$yVersión publicada 000126395 8564_ $$s2522000$$uhttps://zaguan.unizar.es/record/126395/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000126395 909CO $$ooai:zaguan.unizar.es:126395$$particulos$$pdriver 000126395 951__ $$a2024-03-18-15:08:25 000126395 980__ $$aARTICLE